Evaluation of Her2/neu status in carcinomas with amplified chromosome 17 centromere locus

Megan Troxell, Charles D. Bangs, Helen J. Lawce, Ilana B. Galperin, Daniel Baiyee, Robert B. West, Susan Olson, Athena M. Cherry

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Accurate assessment of Her-2/neu (erb-b2) status in breast carcinoma is essential for therapy planning. Clinical assays are targeted at protein overexpression (immunohistochemical analysis) or gene amplification (fluorescence in situ hybridization [FISH]). Cases with aberrant FISH signal patterns are problematic and may lead to underreporting of Her-2/neu amplification. We performed FISH with additional chromosome 17 probes, SMS (Smith-Magenis syndrome critical region) and RARA (retinoic acid receptor), on 7 cases with unusual Her-2/CEP17 (chromosome 17 centromere control probe) results to assess whether different measurements of chromosome 17 copy number might clarify the Her-2/neu amplicon status. Although the Her-2/CEP17 ratio scores were within normal range (<2.0), the Her-2/SMS or Her-2/RARA ratio revealed amplification of Her-2/neu in 5 of 7 cases. Immunohistochemical analysis demonstrated Her-2/neu protein overexpression in the same 5 cases only. We describe novel application of SMS/RARA FISH probes for assessing cases with complex Her-2/CEP17 FISH patterns. Such additional data, correlated with immunohistochemical analysis, may help guide therapy in patients with breast carcinoma.

Original languageEnglish (US)
Pages (from-to)709-716
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume126
Issue number5
DOIs
StatePublished - Jan 1 2006

Fingerprint

Chromosomes, Human, Pair 17
Centromere
Fluorescence In Situ Hybridization
Carcinoma
Smith-Magenis Syndrome
Breast Neoplasms
Retinoic Acid Receptors
Gene Amplification
Reference Values
Proteins
Therapeutics

Keywords

  • Breast carcinoma
  • CEP17
  • erb-b2
  • FISH
  • Fluorescence in situ hybridization
  • Her-2/neu
  • Immunohistochemistry
  • RARA
  • Retinoic acid receptor
  • Smith-Magenis syndrome

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Troxell, M., Bangs, C. D., Lawce, H. J., Galperin, I. B., Baiyee, D., West, R. B., ... Cherry, A. M. (2006). Evaluation of Her2/neu status in carcinomas with amplified chromosome 17 centromere locus. American Journal of Clinical Pathology, 126(5), 709-716. https://doi.org/10.1309/9EYM6VE58F2YCD9F

Evaluation of Her2/neu status in carcinomas with amplified chromosome 17 centromere locus. / Troxell, Megan; Bangs, Charles D.; Lawce, Helen J.; Galperin, Ilana B.; Baiyee, Daniel; West, Robert B.; Olson, Susan; Cherry, Athena M.

In: American Journal of Clinical Pathology, Vol. 126, No. 5, 01.01.2006, p. 709-716.

Research output: Contribution to journalArticle

Troxell, M, Bangs, CD, Lawce, HJ, Galperin, IB, Baiyee, D, West, RB, Olson, S & Cherry, AM 2006, 'Evaluation of Her2/neu status in carcinomas with amplified chromosome 17 centromere locus', American Journal of Clinical Pathology, vol. 126, no. 5, pp. 709-716. https://doi.org/10.1309/9EYM6VE58F2YCD9F
Troxell, Megan ; Bangs, Charles D. ; Lawce, Helen J. ; Galperin, Ilana B. ; Baiyee, Daniel ; West, Robert B. ; Olson, Susan ; Cherry, Athena M. / Evaluation of Her2/neu status in carcinomas with amplified chromosome 17 centromere locus. In: American Journal of Clinical Pathology. 2006 ; Vol. 126, No. 5. pp. 709-716.
@article{a3518dda6f0d4061bab753a96c2c4d5b,
title = "Evaluation of Her2/neu status in carcinomas with amplified chromosome 17 centromere locus",
abstract = "Accurate assessment of Her-2/neu (erb-b2) status in breast carcinoma is essential for therapy planning. Clinical assays are targeted at protein overexpression (immunohistochemical analysis) or gene amplification (fluorescence in situ hybridization [FISH]). Cases with aberrant FISH signal patterns are problematic and may lead to underreporting of Her-2/neu amplification. We performed FISH with additional chromosome 17 probes, SMS (Smith-Magenis syndrome critical region) and RARA (retinoic acid receptor), on 7 cases with unusual Her-2/CEP17 (chromosome 17 centromere control probe) results to assess whether different measurements of chromosome 17 copy number might clarify the Her-2/neu amplicon status. Although the Her-2/CEP17 ratio scores were within normal range (<2.0), the Her-2/SMS or Her-2/RARA ratio revealed amplification of Her-2/neu in 5 of 7 cases. Immunohistochemical analysis demonstrated Her-2/neu protein overexpression in the same 5 cases only. We describe novel application of SMS/RARA FISH probes for assessing cases with complex Her-2/CEP17 FISH patterns. Such additional data, correlated with immunohistochemical analysis, may help guide therapy in patients with breast carcinoma.",
keywords = "Breast carcinoma, CEP17, erb-b2, FISH, Fluorescence in situ hybridization, Her-2/neu, Immunohistochemistry, RARA, Retinoic acid receptor, Smith-Magenis syndrome",
author = "Megan Troxell and Bangs, {Charles D.} and Lawce, {Helen J.} and Galperin, {Ilana B.} and Daniel Baiyee and West, {Robert B.} and Susan Olson and Cherry, {Athena M.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1309/9EYM6VE58F2YCD9F",
language = "English (US)",
volume = "126",
pages = "709--716",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

TY - JOUR

T1 - Evaluation of Her2/neu status in carcinomas with amplified chromosome 17 centromere locus

AU - Troxell, Megan

AU - Bangs, Charles D.

AU - Lawce, Helen J.

AU - Galperin, Ilana B.

AU - Baiyee, Daniel

AU - West, Robert B.

AU - Olson, Susan

AU - Cherry, Athena M.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Accurate assessment of Her-2/neu (erb-b2) status in breast carcinoma is essential for therapy planning. Clinical assays are targeted at protein overexpression (immunohistochemical analysis) or gene amplification (fluorescence in situ hybridization [FISH]). Cases with aberrant FISH signal patterns are problematic and may lead to underreporting of Her-2/neu amplification. We performed FISH with additional chromosome 17 probes, SMS (Smith-Magenis syndrome critical region) and RARA (retinoic acid receptor), on 7 cases with unusual Her-2/CEP17 (chromosome 17 centromere control probe) results to assess whether different measurements of chromosome 17 copy number might clarify the Her-2/neu amplicon status. Although the Her-2/CEP17 ratio scores were within normal range (<2.0), the Her-2/SMS or Her-2/RARA ratio revealed amplification of Her-2/neu in 5 of 7 cases. Immunohistochemical analysis demonstrated Her-2/neu protein overexpression in the same 5 cases only. We describe novel application of SMS/RARA FISH probes for assessing cases with complex Her-2/CEP17 FISH patterns. Such additional data, correlated with immunohistochemical analysis, may help guide therapy in patients with breast carcinoma.

AB - Accurate assessment of Her-2/neu (erb-b2) status in breast carcinoma is essential for therapy planning. Clinical assays are targeted at protein overexpression (immunohistochemical analysis) or gene amplification (fluorescence in situ hybridization [FISH]). Cases with aberrant FISH signal patterns are problematic and may lead to underreporting of Her-2/neu amplification. We performed FISH with additional chromosome 17 probes, SMS (Smith-Magenis syndrome critical region) and RARA (retinoic acid receptor), on 7 cases with unusual Her-2/CEP17 (chromosome 17 centromere control probe) results to assess whether different measurements of chromosome 17 copy number might clarify the Her-2/neu amplicon status. Although the Her-2/CEP17 ratio scores were within normal range (<2.0), the Her-2/SMS or Her-2/RARA ratio revealed amplification of Her-2/neu in 5 of 7 cases. Immunohistochemical analysis demonstrated Her-2/neu protein overexpression in the same 5 cases only. We describe novel application of SMS/RARA FISH probes for assessing cases with complex Her-2/CEP17 FISH patterns. Such additional data, correlated with immunohistochemical analysis, may help guide therapy in patients with breast carcinoma.

KW - Breast carcinoma

KW - CEP17

KW - erb-b2

KW - FISH

KW - Fluorescence in situ hybridization

KW - Her-2/neu

KW - Immunohistochemistry

KW - RARA

KW - Retinoic acid receptor

KW - Smith-Magenis syndrome

UR - http://www.scopus.com/inward/record.url?scp=85047695948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047695948&partnerID=8YFLogxK

U2 - 10.1309/9EYM6VE58F2YCD9F

DO - 10.1309/9EYM6VE58F2YCD9F

M3 - Article

C2 - 17050068

AN - SCOPUS:85047695948

VL - 126

SP - 709

EP - 716

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -